The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 03, 2021

Filed:

Nov. 16, 2020
Applicant:

Cellectis, Paris, FR;

Inventors:

Roman Galetto, Paris, FR;

Julianne Smith, New York, NY (US);

Andrew Scharenberg, Seattle, WA (US);

Cécile Schiffer-Mannioui, Villiers-sur-Marne, FR;

Assignee:

Cellectis, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2501/39 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2502/99 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged 'activated' state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.


Find Patent Forward Citations

Loading…